‌

US Patent 8895745 Bicyclic heterocyclic compounds as FGFR inhibitors

Patent 8895745 was granted and assigned to Astex Therapeutics Limited on November, 2014 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Current Assignee

‌

Astex Therapeutics Limited

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

8895745

Date of Patent

November 25, 2014

Patent Application Number

12520481

Date Filed

December 21, 2007

Patent Citations Received

‌

US Patent 12018017 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

‌

US Patent 12006503 Fusion proteins and methods thereof

‌

US Patent 12123005 Fusion proteins and methods thereof

‌

US Patent 12084438 GCN2 inhibitors and uses thereof

‌

US Patent 11834436 Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

‌

US Patent 11920138 Fusion proteins and methods thereof

Patent Primary Examiner

‌

David K O Dell

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8895745 Bicyclic heterocyclic compounds as FGFR inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API